文献速递妇科

立体定向体部放疗在妇科癌症寡转移中的疗效及人工智能预测缓解

Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
PubMed 文献 · Gynecol Oncol · 2024-01-24

该多中心真实世界数据集纳入21家放疗机构501例妇科癌症患者共846个寡转移灶,分析立体定向体部放疗(SBRT)的疗效与临床结局,并探索机器学习预测完全缓解(CR)。结果显示CR率为63.7%,CR与2年局部控制、无远处转移生存、无进展生存和总生存均显著相关,但机器学习整体预测CR能力有限。

要点

  • 846个妇科癌症寡转移灶中,SBRT后CR率为63.7%(538个病灶)。
  • 全组2年局部控制率为79.2%,CR病灶为91.5%,非CR病灶为52.5%(P < 0.001)。
  • 机器学习整体预测CR能力有限,仅在子宫和卵巢癌亚组中某些因素与CR概率相关。

核心结论

  • 在本组妇科癌症寡转移病灶中,CR与患者结局显著相关,人工智能预测CR可能有助于个体化肿瘤治疗中的治疗选择。

研究设计与样本

  • 多中心真实世界汇总分析,纳入21家放疗机构的501例患者共846个妇科癌症寡转移病灶,主要终点为放疗后CR率,并构建探索性机器学习模型预测CR。

主要发现

  • 846个病灶中,卵巢转移占53.1%,子宫转移占32.1%;762个病灶(90.1%)接受多分次放疗,最常见方案为24 Gy分3次(13.4%)。
  • 538个病灶(63.7%)观察到CR;机器学习分析在全系列中寻找足以预测CR的协变量能力有限。
  • 子宫癌中,放疗剂量≥78.3 Gy时CR概率为75.4%,病灶体积<13.7 cc时CR概率为85.1%;卵巢癌中,病灶为淋巴结时CR概率为71.4%,体积<17 cc时CR概率升至78.4%;宫颈病灶无协变量可预测CR。
  • 全组2年局部控制率为79.2%,CR病灶为91.5%,非CR病灶为52.5%(P < 0.001)。
  • 全组2年无远处转移生存率、无进展生存率和总生存率分别为27.3%、24.8%和71.0%,CR与非CR病灶间差异显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present a large real-world multicentric dataset of ovarian, uterine and cervical oligometastatic lesions treated with SBRT exploring efficacy and clinical outcomes. In addition, an exploratory machine learning analysis was performed. METHODS: A pooled analysis of gynecological oligometastases in terms of efficacy and clinical outcomes as well an exploratory machine learning model to predict the CR to SBRT were carried out. The CR rate following radiotherapy (RT) was the study main endpoint. The secondary endpoints included the 2-year actuarial LC, DMFS, PFS, and OS. RESULTS: 501 patients from 21 radiation oncology institutions with 846 gynecological metastases were analyzed, mainly ovarian (53.1%) and uterine metastases(32.1%).Multiple fraction radiotherapy was used in 762 metastases(90.1%).The most frequent schedule was 24 Gy in 3 fractions(13.4%). CR was observed in 538(63.7%) lesions. The Machine learning analysis showed a poor ability to find covariates strong enough to predict CR in the whole series. Analyzing them separately, in uterine cancer, if RT dose≥78.3Gy, the CR probability was 75.4%; if volume was <13.7 cc, the CR probability became 85.1%. In ovarian cancer, if the lesion was a lymph node, the CR probability was 71.4%; if volume was <17 cc, the CR probability rose to 78.4%. No covariate predicted the CR for cervical lesions. The overall 2-year actuarial LC was 79.2%, however it was 91.5% for CR and 52.5% for not CR lesions(p < 0.001). The overall 2-year DMFS, PFS and OS rate were 27.3%, 24.8% and 71.0%, with significant differences between CR and not CR. CONCLUSIONS: CR was substantially associated to patient outcomes in our series of gynecological cancer oligometastatic lesions. The ability to predict a CR through artificial intelligence could also drive treatment choices in the context of personalized oncology.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Macchia G, Cilla S, Pezzulla D, et al. Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer. Gynecol Oncol. 2024. PMID: 38271773. doi:10.1016/j.ygyno.2024.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。